ScottJones

Of Counsel

Tokyo + 81.3.6800.1813

Scott Jones has 30 years of experience in the fields of M&A, corporate law, and arbitration and represents Japanese clients in their investments overseas and foreign clients in connection with their investments in Japan. He has significant experience in cross-border investments, corporate acquisitions, joint ventures, and licensing agreements. Scott also has significant arbitration experience, having represented clients in proceedings governed by the rules of the American Arbitration Association, the International Chamber of Commerce, and the Japan Commercial Arbitration Association.

A former process engineer with Intel Corporation with an undergraduate degree in chemistry, Scott has a strong technical background and is head of the Life Sciences group in the Tokyo Office. He represents pharmaceutical, chemical, and high-technology companies, both Japanese and foreign, in M&A projects, licensing agreements, and arbitration. Scott represented Daiichi Sankyo in its purchase of a majority equity interest in Ranbaxy Laboratories Limited for approximately US$4 billion and Sumitomo Pharmaceuticals Co. in its merger with Dainippon Pharmaceutical Co. in a transaction valued at approximately US$2 billion. He frequently represents Japanese pharmaceutical clients in negotiating licensing agreements and has represented Japanese pharmaceutical companies in arbitrations with non-Japanese pharmaceutical companies.

Experience

  • M&A
  • Sumitomo Dainippon Pharma acquires Tolero Pharmaceuticals, Inc.Jones Day advised Sumitomo Dainippon Pharma Co. Ltd., a leading pharmaceutical company based in Japan, in its acquisition of Tolero Pharmaceuticals, Inc.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • Sumitomo Chemical acquires remaining 40 percent of Nihon OxiraneJones Day advised Sumitomo Chemical Co., Ltd. in the acquisition of the remaining 40 percent of Nihon Oxirane Co. from joint venture partner LyondellBasell.
  • Dainippon Sumitomo Pharma acquires oncology-focused biotechnology company Boston Biomedical for $200 million plus up to $2.2 billion in earnoutsJones Day advised Dainippon Sumitomo Pharma Co. in its acquisition of Boston Biomedical Inc. ("BBI") for US$200 million plus up to US$2.2 billion in earnouts.
  • Sumitomo Chemical acquires 20% of NuFarm for $622 millionJones Day advised Sumitomo Chemical, a company listed on the Tokyo Stock Exchange ("Sumitomo") in its strategic investment and alliance with Nufarm Limited, a company listed on the Australian Securities Exchange and one of Australia's largest agro-chemical companies with an annual turnover in excess of $2.6 billion.
  • Toray Industries and TonenGeneral Sekiyu K. K. form joint ventureJones Day advised Toray Industries, Inc. in its formation of a joint venture with TonenGeneral Sekiyu K. K. through a new contribution of capital into Tonen Specialty Separator Godo Kaisha to develop, manufacture and sell lithium ion battery separator film.
  • Sumitomo Corporation acquires 35% stake in Hachette FujingahoJones Day advised Sumitomo Corporation in its strategic alliance with and acquisition of a 35% stake in Hachette Fujingaho, a subsidiary of Lagardère SCA.
  • Otsuka Pharmaceutical forms research collaboration with global research organizationJones Day represented Otsuka Pharmaceutical in establishing a research collaboration with an internationally recognized research organization.
  • Daiichi Sankyo acquires generic-drug maker Ranbaxy Laboratories for $4.6 billionJones Day advised Daiichi Sankyo Company, Limited, one of the largest pharmaceutical companies in Japan, in its acquisition of a majority equity interest in Ranbaxy Laboratories Limited, among the world's top 10 generic pharmaceuticals producers and the largest pharmaceutical company in India.
  • Sojitz acquires CymetechJones Day advised Sojitz Corporation in its acquisition of Cymetech, LLC.
  • Canon Sales sells remaining 50% interest in Canon Staar to joint venture partner STAAR Surgical CompanyJones Day advised Canon Sales Co., Ltd. in its sale of the remaining 50% interest in Canon Staar Co., Inc. to joint venture partner STAAR Surgical Company.
  • Parker Hannifin acquires 70% of the shares of Kuroda PneumaticsJones Day advised Parker Hannifin Corporation in its 70% acquisition of the shares of Kuroda Pneumatics Ltd., a wholly owned subsidiary of Kuroda Precision Industries Ltd.
  • Sumitomo Pharmaceuticals merges with Dainippon PharmaceuticalJones Day advised Sumitomo Chemical Co., Ltd. (Sumitomo) and Sumitomo Pharmaceuticals Co., Ltd. (SumiPharm) in the $2.2 billion merger of SumiPharm with Dainippon Pharmaceutical Co., Ltd. (Dainippon).
  • Arbitration / Litigation
  • Japanese pharmaceutical company arbitrates intellectual property dispute with U.S. companyJones Day is representing a Japanese pharmaceutical company involved in an ICC arbitration with a U.S. pharmaceutical company regarding intellectual property rights.
  • Japanese pharmaceutical company prevails in ICC arbitrationJones Day successfully represented a Japanese pharmaceutical company in an ICC arbitration with a U.S. pharmaceutical company regarding a contractual and intellectual property dispute in France.
  • Shionogi obtains settlement entitling it to royalties on European Union sales of drug for treatment of fatal lung diseaseJones Day represented Shionogi & Co., Ltd. in a royalty dispute with InterMune, Inc. concerning sales of Esbriet® for treatment of Idiopathic Pulmonary Fibrosis ("IPF"), obtaining a settlement entitling Shionogi to royalties on InterMune's sales in the European Union.
  • The following represents experience prior to Jones Day:

    M&A

    Represented Atofina in sale of interest in chemical manufacturing joint venture in Japan.

    Represented Inchcape International Group B.V. in sale of Japanese subsidiary.

    Represented Japanese electronics company in sale of interests in several privately held California high technology companies.

    Represented Japanese hotel company in purchase of hotel in New York City.

    Represented Lycos, Inc. in joint venture with Sumitomo Corporation and several other Japanese entities.

    Represented major Japanese airline in sale of equity interest in DHL.

    Represented Omnivision Latinamerican Entertainment in joint venture with HBO for the distribution of Spanish language cable programming in Latin America.

    Represented Sumitomo Chemical Company in purchase of insecticide business.

    Represented The Long Term Credit Bank of Japan in sale of integrated island resort to Sheraton.

    Arbitration

    Represented French medical devices company in taking distribution agreement dispute with American orthopedic project manufacturer to arbitration before the AAA.

    Represented German apparel company in taking distribution agreement dispute with Japanese sportswear company to arbitration before the JCAA.

  • Additional Publications

    • January 2018
      Law and Practice Japan, Pharmaceutical Advertising, Chambers Global Practice Guides
    • June 2005
      Hostile Takeover Attempt and Poison Pills in a Japanese Way: Livedoor vs. Fuji TV over Nippon Broadcasting, The M&A Lawyer
    • May 2005
      Basic Understandings of M&A Agreements I/II, M&A Review

    Speaking Engagements

    • August 2019
      医薬品企業法務研究会:実践的な英文ライセンス契約
    • September 2018
      ジョーンズ・デイ セミナー:国際的なライセンス契約に関する契約上および税務上の留意点
    • May 2018 (Day 2)
      ジョーンズ・デイ ライフサイエンスセミナー:医薬品、医療機器、ビッグデータ、IoT -ライフサイエンス企業が2018年に直面している法的問題 -
    • May 2018 (Day 1)
      ジョーンズ・デイ ライフサイエンスセミナー:医薬品、医療機器、ビッグデータ、IoT -ライフサイエンス企業が2018年に直面している法的問題 -
    • September 2017
      ジョーンズ・デイ ライフサイエンスセミナー:ライフサイエンス業界におけるM&Aの最新動向
    • April 2017
      ジョーンズ・デイ ライフサイエンスセミナー:医薬品に関する国際契約書の作成・交渉(2)
    • April 2017
      ジョーンズ・デイ ライフサイエンスセミナー:医薬品に関する国際契約書の作成・交渉(1)
    • December 7
      ジョーンズ・デイ ライフサイエンスセミナー:中国の法規制及び法執行の発展により生じているライフサイエンス企業及び製薬企業の新たな課題
    • February 2016
      米国商務省SelectUSA:米国におけるM&A ―HSR法及びCFIUSに関する届出―
    • September 2015
      ライフサイエンス業界における法執行及びコンプライアンスの最新動向
    • September 2015
      医薬品企業法務研究会:日米欧での適応外使用問題とその対応
    • September 2013
      ジョーンズ・デイ・ビデオセミナー:米国医療費負担適正化法が日本企業に及ぼす影響について
    • November 2011
      日本化学繊維協会セミナー:化学品供給における不可抗力
    • November 2011
      Force Majeure Clauses in Supply Agreements under U.S and EU Law, Japan Chemical Fibers Association
    • June 21, 2005
      Hostile Takeovers and Cross-Border M&A, Ihoken (Japanese Pharmaceutical Industry Legal Affairs Association)
    • March 14, 2005
      U.S. Cross-Border M&A and its Application to Japan, Keio Academic Enterprise Co., Ltd.
    • March 14, 2005
      U.S. Cross-Border M&A and Its Application to Japan, M&A Forum
    • October 01, 2004
      Doing Business in Greater China and Asia, a presentation for Jones Day clients and colleagues,  Jones Day, Pittsburgh
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.